Psychiatric care of the patient with hepatitis c: A review of the literature

Primary Care Companion to the Journal of Clinical Psychiatry

Volumn 12, Issue 6, 2010, Pages

  Rifai, Muhamad Aly ^a   Gleason, Ondria C ^b   Sabouni, Douha ^c  

^a PENN STATE COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF OKLAHOMA   (United States)

^c St Joesph Regional Medical Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; CITALOPRAM; ESCITALOPRAM; INTERFERON; LITHIUM CARBONATE; NEFAZODONE; PAROXETINE; PEGINTERFERON ALPHA; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RIBAVIRIN;

AGGRESSION; AGITATION; ANXIETY DISORDER; COGNITIVE DEFECT; DEPRESSION; DRUG INDUCED HEADACHE; DRUG WITHDRAWAL; FATIGUE; GASTROINTESTINAL SYMPTOM; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HYPOMANIA; INSOMNIA; IRRITABILITY; LIVER TOXICITY; MANIA; MEDICAL PRACTICE; MENTAL DISEASE; MENTAL HEALTH CARE; MOOD DISORDER; MORTALITY; NONHUMAN; PATIENT COUNSELING; PREVALENCE; PRIMARY MEDICAL CARE; PSYCHOPATHY; PSYCHOSIS; REVIEW; RISK BENEFIT ANALYSIS; RISK FACTOR; SIDE EFFECT; SUICIDAL IDEATION; SUICIDE; SUICIDE ATTEMPT; VIRUS TRANSMISSION;

EID: 79251481077     PISSN: 15235998     EISSN: 1555211X     Source Type: Journal    
DOI: 10.4088/PCC.09r00877whi     Document Type: Review

References (134)

1. Alter HJ, Holland PV, Purcell RH, et al. Posttransfusion hepatitis after exclusion of commercial and hepatitis-B antigen-positive donors. Ann Intern Med. 1972;77(5):691-699.
2. Alter HJ. Descartes before the horse: I clone, therefore I am: the hepatitis C virus in current perspective. Ann Intern Med. 1991;115(8):644-649.
3. Alter H. Discovery of non-A, non-B hepatitis and identification of its etiology. Am J Med. 1999;107(suppl 2):16-20. doi:10.1016/S0002-9343(99)00375-7
4. Hoofnagle JH, Mullen KD, Jones DB, et al. Treatment of chronic non-A, non-B hepatitis with recombinant human alpha interferon: a preliminary report. N Engl J Med. 1986;315(25):1575-1578.
5. Renault PF, Hoofnagle JH, Park Y, et al. Psychiatric complications of long-term interferon alfa therapy. Arch Intern Med. 1987;147(9):1577-1580.
6. Renault PF, Hoofnagle JH. Side effects of alpha interferon. Semin Liver Dis. 1989;9(4):273-277.
7. Gleason OC, Yates WR. Five cases of interferon-alpha-induced depression treated with antidepressant therapy. Psychosomatics. 1999;40(6):510-512.
8. Hauser P, Soler R, Reed S, et al. Prophylactic treatment of depression induced by interferon-alpha. Psychosomatics. 2000;41(5):439-441.
9. Yovtcheva SP, Rifai MA, Moles JK, et al. Psychiatric co-morbidities in veterans with hepatitis C at the Salem Veterans Affairs Medical Center. Med Psychiatry. 2001;4(1):42.
10. Yovtcheva SP, Rifai MA, Moles JK, et al. Psychiatric comorbidity among hepatitis C-positive patients. Psychosomatics. 2001;42(5):411-415.
11. Yovtcheva SP, Rifai MA, Moles JK, et al. Psychiatric comorbidity among hepatitis C-positive patients. Focus. 2005;3(2):261-265.
12. Hauser P, Khosla J, Aurora H, et al. A prospective study of the incidence and open-label treatment of interferon-induced major depressive disorder in patients with hepatitis C. Mol Psychiatry. 2002;7(9):942-947.
13. Gleason OC, Yates WR, Isbell MD, et al. An open-label trial of citalopram for major depression in patients with hepatitis C. J Clin Psychiatry. 2002;63(3):194-198.
14. Seeff LB. Natural history of hepatitis C. Am J Med. 1999;107(suppl 2):10-15. doi:10.1016/S0002-9343(99)00374-5
15. MJ. Epidemiology of hepatitis C. Hepatology. 1997;26(suppl 1):62S-65S.
16. Armstrong GL, Alter MJ, McQuillan GM, et al. The past incidence of hepatitis C virus infection: implications for the future burden of chronic liver disease in the United States. Hepatology. 2000;31(3):777-782.
17. Armstrong GL, Wasley A, Simard EP, et al. The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Ann Intern Med. 2006;144(10):705-714.
18. Ghany MG, Strader DB, Thomas DL, et al. American Association for the Study of Liver Diseases. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology. 2009;49(4):1335-1374.
19. Alter MJ. Prevention of spread of hepatitis C. Hepatology. 2002;36(suppl 1):S93-S98.
20. Alter MJ, Seeff LB, Bacon BR, et al. Testing for hepatitis C virus infection should be routine for persons at increased risk for infection. Ann Intern Med. 2004;141(9):715-717.
21. Poynard T, Yuen M-F, Ratziu V, et al. Viral hepatitis C. Lancet. 2003;362(9401):2095-2100.
22. Osher FC, Goldberg RW, McNary SW, et al. Five-Site Health and Risk Study Research Committee. Substance abuse and the transmission of hepatitis C among persons with severe mental illness. Psychiatr Serv. 2003;54(6):842-847.
23. McMahon JM, Tortu S. A potential hidden source of hepatitis C infection among noninjecting drug users. J Psychoactive Drugs. 2003;35(4):455-460.
24. Rifai MA, Moles JK, Van Der Linden BJ. Hepatitis C screening in patients with substance abuse/dependence disorders. Psychosomatics. 2004;45(2):159-160.
25. Dinwiddie SH, Shicker L, Newman T. Prevalence of hepatitis C among psychiatric patients in the public sector. Am J Psychiatry. 2003;160(1):172-174.
26. Rifai MA, Van Der Linden BJ, Moles JK. Abstracts From the 2001 Annual Meeting of the Association of Medicine and Psychiatry. The prevalence of psychiatric disorders in veterans with chronic hepatitis C infection: impact on screening [abstract]. Prim Care Companion J Clin Psychiatry. 2002;4(4):163.
27. Rifai MA, Moles JK, Van Der Linden BJ. The prevalence of psychiatric disorders in patients with chronic hepatitis C. Psychosomatics. 2003;44(2):142-143.
28. Sloan KL, Straits-Tröster KA, Dominitz JA, et al. Hepatitis C tested prevalence and comorbidities among veterans in the US Northwest. J Clin Gastroenterol. 2004;38(3):279-284.
29. Cheung RC. Epidemiology of hepatitis C virus infection in American veterans. Am J Gastroenterol. 2000;95(3):740-747.
30. Weinbaum C, Lyerla R, Margolis HS. Centers for Disease Control and Prevention. Prevention and control of infections with hepatitis viruses in correctional settings. MMWR Recomm Rep. 2003;52(RR-1):1-36, quiz CE1-CE4.
31. Rifai MA, Moles JK, Short DD. Hepatitis C treatment eligibility and outcomes among patients with psychiatric illness. Psychiatr Serv. 2006;57(4):570-572.
32. Forton DM, Taylor-Robinson SD, Thomas HC. Cerebral dysfunction in chronic hepatitis C infection. J Viral Hepat. 2003;10(2):81-86.
33. Forton DM, Thomas HC, Taylor-Robinson SD. Central nervous system involvement in hepatitis C virus infection. Metab Brain Dis. 2004;19(3-4):383-391.
34. Weissenborn K, Tryc AB, Heeren M, et al. Hepatitis C virus infection and the brain. Metab Brain Dis. 2009;24(1):197-210.
35. Poynard T, Cacoub P, Ratziu V, et al. Multivirc group. Fatigue in patients with chronic hepatitis C. J Viral Hepat. 2002;9(4):295-303.
36. Huckans M, Seelye A, Parcel T, et al. The cognitive effects of hepatitis C in the presence and absence of a history of substance use disorder. J Int Neuropsychol Soc. 2009;15(1):69-82.
37. Forton DM, Thomas HC, Murphy CA, et al. Hepatitis C and cognitive impairment in a cohort of patients with mild liver disease. Hepatology. 2002;35(2):433-439.
38. Weissenborn K, Krause J, Bokemeyer M, et al. Hepatitis C virus infection affects the brain-evidence from psychometric studies and magnetic resonance spectroscopy. J Hepatol. 2004;41(5):845-851.
39. Lowry D, Coughlan B, McCarthy O, et al. Investigating health-related quality of life, mood and neuropsychological test performance in a homogeneous cohort of Irish female hepatitis C patients. J Viral Hepat. 2010;17(5):352-359.
40. Radkowski M, Gallegos-Orozco JF, Jablonska J, et al. Persistence of hepatitis C virus in patients successfully treated for chronic hepatitis C. Hepatology. 2005;41(1):106-114.
41. Vargas HE, Laskus T, Radkowski M, et al. Detection of hepatitis C virus sequences in brain tissue obtained in recurrent hepatitis C after liver transplantation. Liver Transpl. 2002;8(11):1014-1019.
42. Radkowski M, Wilkinson J, Nowicki M, et al. Search for hepatitis C virus negative-strand RNA sequences and analysis of viral sequences in the central nervous system: evidence of replication. J Virol. 2002;76(2):600-608.
43. Laskus T, Radkowski M, Bednarska A, et al. Detection and analysis of hepatitis C virus sequences in cerebrospinal fluid. J Virol. 2002;76(19):10064-10068.
44. Forton DM, Karayiannis P, Mahmud N, et al. Identification of unique hepatitis C virus quasispecies in the central nervous system and comparative analysis of internal translational efficiency of brain, liver, and serum variants. J Virol. 2004;78(10):5170-5183.
45. Forton DM, Allsop JM, Main J, et al. Evidence for a cerebral effect of the hepatitis C virus. Lancet. 2001;358(9275):38-39.
46. Forton DM, Wright M, Knapp S, et al. New insights into hepatitis C. Clin Med. 2002;2(6):554-559.
47. el-Serag HB, Kunik M, Richardson P, et al. Psychiatric disorders among veterans with hepatitis C infection. Gastroenterology. 2002;123(2):476-482.
48. Lehman CL, Cheung RC. Depression, anxiety, post-traumatic stress, and alcohol-related problems among veterans with chronic hepatitis C. Am J Gastroenterol. 2002;97(10):2640-2646.
49. Regier DA, Narrow WE, Rae DS, et al. The de facto US mental and addictive disorders service system: epidemiologic catchment area prospective 1-year prevalence rates of disorders and services. Arch Gen Psychiatry. 1993;50(2):85-94.
50. Norquist GS, Regier DA. The epidemiology of psychiatric disorders and the de facto mental health care system. Annu Rev Med. 1996;47:473-479.
51. Al Jurdi RK, Burruss JW. Prevalence of hepatitis C in psychiatric institutions. Psychosomatics. 2003;44(5):439-440.
52. Sabouni D, Rifai MA, Moles JK, et al. Hepatitis C treatment eligibility and outcomes in patients with psychiatric illness. Am J Gastroenterol. 2005;100(9):S117-S118. doi:10.1111/j.1572-0241.2005.001_5.x
53. Nakamura Y, Koh M, Miyoshi E, et al. High prevalence of the hepatitis C virus infection among the inpatients of schizophrenia and psychoactive substance abuse in Japan. Prog Neuropsychopharmacol Biol Psychiatry. 2004;28(3):591-597.
54. Chang TT, Lin H, Yen YS, et al. Hepatitis B and hepatitis C among institutionalized psychiatric patients in Taiwan. J Med Virol. 1993;40(2):170-173.
55. Eveillard M, Daroukh A, Desjardins P, et al. Seroprevalence of hepatitis B and C viruses in a psychiatric institution. Pathol Biol (Paris). 1999;47(5):543-548.
56. Kakisi OK, Grammatikos AA, Karageorgopoulos DE, et al. Prevalence of hepatitis B, hepatitis C, and HIV infections among patients in a psychiatric hospital in Greece. Psychiatr Serv. 2009;60(9):1269-1272.
57. Cividini A, Pistorio A, Regazzetti A, et al. Hepatitis C virus infection among institutionalised psychiatric patients: a regression analysis of indicators of risk. J Hepatol. 1997;27(3):455-463.
58. Sawayama Y, Hayashi J, Kakuda K, et al. Hepatitis C virus infection in institutionalized psychiatric patients: possible role of transmission by razor sharing. Dig Dis Sci. 2000;45(2):351-356.
59. Stroffolini T, Marchi L, Brunetti E, et al. Lack of hepatitis C transmission among institutionalized psychiatric patients. J Hepatol. 2003;38(2):244.
60. Huckans MS, Blackwell AD, Harms TA, et al. Management of hepatitis C disease among VA patients with schizophrenia and substance use disorders. Psychiatr Serv. 2006;57(3):403-406.
61. Huckans M, Mitchell A, Ruimy S, et al. Antiviral therapy completion and response rates among hepatitis C patients with and without schizophrenia. Schizophr Bull. 2010;36(1):165-172.
62. Crone CC, Gabriel GM, Wise TN. Managing the neuropsychiatric side effects of interferon-based therapy for hepatitis C. Cleve Clin J Med. 2004;71(suppl 3):S27-S32.
63. Crone C, Gabriel GM. Comprehensive review of hepatitis C for psychiatrists: risks, screening, diagnosis, treatment, and interferon-based therapy complications. J Psychiatr Pract. 2003;9(2):93-110.
64. Flamm SL. Chronic hepatitis C virus infection. JAMA. 2003;289(18):2413-2417.
65. Alter MJ, Kuhnert WL, Finelli L. Centers for Disease Control and Prevention. Guidelines for laboratory testing and result reporting of antibody to hepatitis C virus. MMWR Recomm Rep. 2003;52(RR-3):1-13, 15, quiz CE1-CE4.
66. Allen SA, Spaulding AC, Osei AM, et al. Treatment of chronic hepatitis C in a state correctional facility. Ann Intern Med. 2003;138(3):187-190.
67. Rifai MA, Moles JK, Lehman LP, et al. Hepatitis C screening and treatment outcomes in patients with substance use/dependence disorders. Psychosomatics. 2006;47(2):112-121.
68. Rifai MA, Loftis JM, Hauser P. Hepatitis C treatment of veterans with psychiatric illness. Am J Gastroenterol. 2006;101(3):673-674, author reply 674-675.
69. Chou R, Clark EC, Helfand M. US Preventive Services Task Force. Screening for hepatitis C virus infection: a review of the evidence for the US Preventive Services Task Force. Ann Intern Med. 2004;140(6):465-479.
70. Strader DB, Wright T, Thomas DL, et al. American Association for the Study of Liver Diseases. Diagnosis, management, and treatment of hepatitis C. Hepatology. 2004;39(4):1147-1171.
71. Wong JB, McQuillan GM, McHutchison JG, et al. Estimating future hepatitis C morbidity, mortality, and costs in the United States. Am J Public Health. 2000;90(10):1562-1569.
72. Duberg AS, Törner A, Davidsdóttir L, et al. Cause of death in individuals with chronic HBV and/or HCV infection, a nationwide community-based register study. J Viral Hepat. 2008;15(7):538-550.
73. Rifai MA, Moles JK, Van der Linden BJ. Hepatitis C and post-traumatic stress disorder in US veterans. Am J Gastroenterol. 98(9 suppl 1):S99-S100.
74. Dan AA, Martin LM, Crone C, et al. Depression,anemia and health-related quality of life in chronic hepatitis C. J Hepatol. 2006;44(3):491-498.
75. Rifai MA. To screen or not to screen for hepatitis C. Psychiatr Serv. 2010;61(3):325-326
76. National Institutes of Health. National Institutes of Health Consensus Development Conference Statement: Management of hepatitis C: 2002: June 10-12, 2002. Hepatology. 2002;36(suppl 1):S3-S20.
77. Sulkowski MS, Thomas DL. Hepatitis C in the HIV-infected person. Ann Intern Med. 2003;138(3):197-207.
78. Peters MG, Terrault NA. Alcohol use and hepatitis C. Hepatology. 2002;36(suppl 1):S220-S225.
79. Lieber CS. Hepatitis C and alcohol. J Clin Gastroenterol. 2003;36(2):100-102.
80. Anand BS, Currie S, Dieperink E, et al. VA-HCV-001 Study Group. Alcohol use and treatment of hepatitis C virus: results of a national multicenter study. Gastroenterology. 2006;130(6):1607-1616.
81. Rifai MA, Rosestein DL. Interferon treatment of hepatitis C patients with psychiatric disorders: evidence-based, risk-benefit assessment. Psychosomatics. 2005;46(2):165-166.
82. Rifai MA, Bozorg B, Rosenstein DL. Interferon for hepatitis C patients with psychiatric disorders. Am J Psychiatry. 2004;161(12):2331-2332, author reply 2332-2334.
83. Rifai MA, Loftis JM, Hauser P. Interferon-alpha treatment of patients with Hepatitis C: the role of a comprehensive risk-benefit assessment. CNS Drugs. 2005;19(8):719-721, author reply 721-722.
84. Rifai MA. Ethical impasses in the care of patients with hepatitis C. Psychosomatics. 2006;47(6):540-541.
85. Rifai MA, Rosestein DL. Hepatitis C and psychiatry. Focus. 2005;3:194-202.
86. Ho SB, Groessl E, Dollarhide A, et al. Management of chronic hepatitis C in veterans: the potential of integrated care models. Am J Gastroenterol. 2008;103(7):1810-1823.
87. Knott A, Dieperink E, Willenbring ML, et al. Integrated psychiatric/medical care in a chronic hepatitis C clinic: effect on antiviral treatment evaluation and outcomes. Am J Gastroenterol. 2006;101(10):2254-2262.
88. Rifai MA. Interferon-alpha treatment of hepatitis C patients with psychiatric illness: evidence-based risk-benefit assessment [letter]. Prim Care Companion J Clin Psychiatry. 2005;7(2):74-75.
89. Rifai MA, Indest D, Loftis J, et al. Psychiatric management of the hepatitis C patient. Curr Treat Options Gastroenterol. 2006;9(6):508-519.
90. Geppert CMA, Dettmer E, Jakiche A. Ethical challenges in the care of persons with hepatitis C infection: a pilot study to enhance informed consent with veterans. Psychosomatics. 2005;46(5):392-401.
91. Gleason O, Fucci J, Yates W. Gastroenterologists' perceptions of need and availability of psychiatric services for patients with hepatitis C. Psychosomatics. 2008;49(2):132-136.
92. Falck-Ytter Y, Kale H, Mullen KD, et al. Surprisingly small effect of antiviral treatment in patients with hepatitis C. Ann Intern Med. 2002;136(4):288-292.
93. Cawthorne CH, Rudat KR, Burton MS, et al. Limited success of HCV antiviral therapy in United States veterans. Am J Gastroenterol. 2002;97(1):149-155.
94. Hauser P, Morasco BJ, Linke A, et al. Antiviral completion rates and sustained viral response in hepatitis C patients with and without preexisting major depressive disorder. Psychosomatics. 2009;50(5):500-505.
95. Silberbogen AK, Ulloa EW, Janke EA, et al. Psychosocial issues and mental health treatment recommendations for patients with hepatitis C. Psychosomatics. 2009;50(2):114-122.
96. Fleming CA, Craven DE, Thornton D, et al. Hepatitis C virus and human immunodeficiency virus coinfection in an urban population: low eligibility for interferon treatment. Clin Infect Dis. 2003;36(1):97-100.
97. Strader DB. Understudied populations with hepatitis C. Hepatology. 2002;36(suppl 1):S226-S236.
98. Taylor LE, Costello T, Alt E, et al. Psychiatric illness and illicit drugs as barriers to hepatitis C treatment among HIV/hepatitis C virus co-infected individuals. AIDS. 2002;16(12):1700-1701.
99. Schaefer M, Schmidt F, Folwaczny C, et al. Adherence and mental side effects during hepatitis C treatment with interferon alfa and ribavirin in psychiatric risk groups. Hepatology. 2003;37(2):443-451.
100. Fried R, Monnat M, Seidenberg A, et al. Swiss multicenter study evaluating the efficacy, feasibility and safety of peginterferon-alfa-2a and ribavirin in patients with chronic hepatitis C in official opiate substitution programs. Digestion. 2008;78(2-3):123-130.
101. Dell'Osso L, Pini S, Maggi L, et al. Subthreshold mania as predictor of depression during interferon treatment in HCV+ patients without current or lifetime psychiatric disorders. J Psychosom Res. 2007;62(3):349-355.
102. Schaefer M, Schmidt F, Horn M, et al. Depression during treatment with interferon alpha. Psychosomatics. 2004;45(2):176.
103. Schaefer M, Heinz A, Backmund M. Treatment of chronic hepatitis C in patients with drug dependence: time to change the rules? Addiction. 2004;99(9):1167-1175.
104. Schäfer M, Schwaiger M. Incidence, pathoetiology and treatment of interferon-alpha induced neuro-psychiatric side effects. Fortschr Neurol Psychiatr. 2003;71(9):469-476.
105. Alvarez-Uria G, Day JN, Nasir AJ, et al. Factors associated with treatment failure of patients with psychiatric diseases and injecting drug users in the treatment of genotype 2 or 3 hepatitis C chronic infection. Liver Int. 2009;29(7):1051-1055.
106. Rifai MA. Hepatitis C treatment of patients with bipolar disorder: a case series. Prim Care Companion J Clin Psychiatry. 2006;8(6):361-366.
107. Gohier B, Goeb JL, Rannou-Dubas K, et al. Hepatitis C, alpha interferon, anxiety and depression disorders: a prospective study of 71 patients. World J Biol Psychiatry. 2003;4(3):115-118.
108. Kraus MR, Schäfer A, Faller H, et al. Psychiatric symptoms in patients with chronic hepatitis C receiving interferon alfa-2b therapy. J Clin Psychiatry. 2003;64(6):708-714.
109. Kraus MR, Schäfer A, Faller H, et al. Paroxetine for the treatment of interferon-alpha-induced depression in chronic hepatitis C. Aliment Pharmacol Ther. 2002;16(6):1091-1099.
110. Schaefer M, Engelbrecht MA, Gut O, et al. Interferon alpha (IFNalpha) and psychiatric syndromes: a review. Prog Neuropsychopharmacol Biol Psychiatry. 2002;26(4):731-746.
111. Dan AA, Crone C, Wise TN, et al. Anger experiences among hepatitis C patients: relationship to depressive symptoms and health-related quality of life. Psychosomatics. 2007;48(3):223-229.
112. Constant A, Castera L, Quintard B, et al. Psychosocial factors associated with perceived disease severity in patients with chronic hepatitis C: relationship with information sources and attentional coping styles. Psychosomatics. 2005;46(1):25-33.
113. Constant A, Castera L, Dantzer R, et al. Mood alterations during interferon-alfa therapy in patients with chronic hepatitis C: evidence for an overlap between manic/hypomanic and depressive symptoms. J Clin Psychiatry. 2005;66(8):1050-1057.
114. Dieperink E, Ho SB, Tetrick L, et al. Suicidal ideation during interferon-alpha2b and ribavirin treatment of patients with chronic hepatitis C. Gen Hosp Psychiatry. 2004;26(3):237-240.
115. Ademmer K, Beutel M, Bretzel R, et al. Suicidal ideation with IFN-alpha and ribavirin in a patient with hepatitis C. Psychosomatics. 2001;42(4):365-367.
116. Gochee PA, Powell EE, Purdie DM, et al. Association between apolipoprotein E epsilon4 and neuropsychiatric symptoms during interferon alpha treatment for chronic hepatitis C. Psychosomatics. 2004;45(1):49-57.
117. Lotrich FE, Ferrell RE, Rabinovitz M, et al. Risk for depression during interferon-alpha treatment is affected by the serotonin transporter polymorphism. Biol Psychiatry. 2009;65(4):344-348.
118. Yoshida K, Alagbe O, Wang X, et al. Promoter polymorphisms of the interferon-alpha receptor gene and development of Interferon-induced depressive symptoms in patients with chronic hepatitis C: preliminary findings. Neuropsychobiology. 2005;52(2):55-61.
119. Kraus MR, Al-Taie O, Schäfer A, et al. Serotonin-1A receptor gene HTR1A variation predicts interferon-induced depression in chronic hepatitis C. Gastroenterology. 2007;132(4):1279-1286.
120. Prather AA, Rabinovitz M, Pollock BG, et al. Cytokine-induced depression during IFN-alpha treatment: the role of IL-6 and sleep quality. Brain Behav Immun. 2009;23(8):1109-1116.
121. Thome J, Knopf U. Acute psychosis after injection of pegylated interferon alpha-2a. Eur Psychiatry. 2003;18(3):142-143.
122. Quarantini LC, Cruz SC, Batista-Neves SC, et al. Psychosis during peginterferon-alpha 2a and ribavirin therapy: case report. Braz J Infect Dis. 2006;10(6):406-407.
123. Telio D, Sockalingam S, Stergiopoulos V. Persistent psychosis after treatment with interferon alpha: a case report. J Clin Psychopharmacol. 2006;26(4):446-447.
124. Gleason OC, Fucci JC, Yates WR, et al. Preventing relapse of major depression during interferon-alpha therapy for hepatitis C-a pilot study. Dig Dis Sci. 2007;52(10):2557-2563.
125. Morasco BJ, Rifai MA, Loftis JM, et al. A randomized trial of paroxetine to prevent interferon-alpha-induced depression in patients with hepatitis C. J Affect Disord. 2007;103(1-3):83-90.
126. Schaefer M, Schwaiger M, Garkisch AS, et al. Prevention of interferon-alpha associated depression in psychiatric risk patients with chronic hepatitis C. J Hepatol. 2005;42(6):793-798.
127. Raison CL, Woolwine BJ, Demetrashvili MF, et al. Paroxetine for prevention of depressive symptoms induced by interferon-alpha and ribavirin for hepatitis C. Aliment Pharmacol Ther. 2007;25(10):1163-1174.
128. Kraus MR, Schäfer A, Al-Taie O, et al. Prophylactic SSRI during interferon alpha re-therapy in patients with chronic hepatitis C and a history of interferon-induced depression. J Viral Hepat. 2005;12(1):96-100.
129. Hejny C, Sternberg P, Lawson DH, et al. Retinopathy associated with high-dose interferon alfa-2b therapy. Am J Ophthalmol. 2001;131(6):782-787.
130. Loftis JM, Hauser P. Safety of the treatment of interferon-alpha-induced depression. Psychosomatics. 2003;44(6):524-526.
131. Ozcanli T, Unsalver B, Ozdemir S, et al. Sertraline- and mirtazapine-induced severe neutropenia. Am J Psychiatry. 2005;162(7):1386.
132. Choi S. Nefazodone (Serzone) withdrawn because of hepatotoxicity. CMAJ. 2003;169(11):1187.
133. Rosenberg SD, Goodman LA, Osher FC, et al. Prevalence of HIV, hepatitis B, and hepatitis C in people with severe mental illness. Am J Public Health. 2001;91(1):31-37.
134. Rosenberg SD, Swanson JW, Wolford GL, et al. Five-Site Health and Risk Study Research Committee. The five-site health and risk study of blood-borne infections among persons with severe mental illness. Psychiatr Serv. 2003;54(6):827-835.